SOUTH
SAN FRANCISCO, Calif., Sept. 27,
2024 /PRNewswire/ -- IDEAYA Biosciences, Inc.
(NASDAQ: IDYA), a precision medicine oncology company committed to
the discovery and development of targeted therapeutics, today
announced that, on September 26,
2024, the Compensation Committee of IDEAYA's Board of
Directors granted non-qualified stock options to purchase an
aggregate of 140,000 shares of the Company's common stock to a
newly hired employee. The stock options were granted under the
IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award
Plan (2023 Inducement Plan) as an inducement material to such
individual entering into employment with IDEAYA in accordance with
Nasdaq Listing Rule 5635(c)(4).
The 2023 Inducement Plan is used exclusively for the grant of
equity awards to individuals who were not previously employees of
IDEAYA, or following a bona fide period of non-employment, as an
inducement material to such individuals' entering into employment
with IDEAYA, pursuant to Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of $30.50 per share, which is equal to the closing
price of IDEAYA's common stock on The Nasdaq Global Select Market
on the date of grant. The stock options have a 10-year term and
will vest over four years, with 25% of the options vesting on the
first anniversary of the vesting commencement date and the
remaining 75% of the options vesting in equal monthly installments
over the three years thereafter. Vesting of the stock options is
subject to such employee's continued service to IDEAYA on each
vesting date.
About IDEAYA Biosciences
IDEAYA is a precision
medicine oncology company committed to the discovery and
development of targeted therapeutics for patient populations
selected using molecular diagnostics. IDEAYA's approach integrates
capabilities in identifying and validating translational biomarkers
with drug discovery to select patient populations most likely to
benefit from its targeted therapies. IDEAYA is applying its early
research and drug discovery capabilities to synthetic lethality –
which represents an emerging class of precision medicine
targets.
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
Senior Vice President, Head of Finance and Investor Relations
investor@ideayabio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302260793.html
SOURCE IDEAYA Biosciences, Inc.